Buy & Sell Albertsons Companies Inc (ACI) – Albertsons Companies Inc Price Today
Aura AI Summary
Key Stats
- $7.87BMarket Cap
- Consumer StaplesSector
- -14.68%3M Drawdown
- $22.97BEnterprise Value
- 4.27%Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 36 daysTypical Hold Time
Albertsons Companies Inc (ACI) is currently valued at a market capitalization of $7.87B, with an enterprise value of $22.97B. Over the past 52 weeks, Albertsons Companies Inc has traded between a low of $15.92 and a high of $22.74, highlighting its annual price range. Over the past three months, Albertsons Companies Inc has recorded a drawdown of -14.68%, reflecting recent price volatility. Albertsons Companies Inc offers a dividend yield of 4.27%, with the most recent dividend of $0.17 paid on 24 Apr 26. On average, investors hold Albertsons Companies Inc for approximately 36 days, indicating typical investor behavior on the platform.
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Most Recent News
Global colorectal cancer diagnostics and therapeutics market to grow at ~9% CAGR, reaching $73B by 2034
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
AI in life sciences market set to grow at 20% CAGR, reaching $11.5B by 2034 driven by drug discovery and data analytics.
The global AI in life sciences market is projected to expand at a compound annual growth rate (CAGR) of about 20% from 2026 to 2034, reaching an estimated value of $11.5 billion. This growth is fueled by increasing demand for faster drug discovery, p...
New data shows Wegovy pill leads to significant long-term weight loss and improved physical function.
Novo Nordisk presented new phase 3 trial data showing that adults taking the Wegovy pill (oral semaglutide 25 mg) achieved meaningful weight loss, with early responders losing up to 21.6% body weight by week 64. Even those not classified as early res...